Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight

globenewswire.com
JAZZ Mentioned as a key company in the AML market, indicating active involvement in the therapeutic area. PRE Included as a key company in the AML market, suggesting active involvement in the development of AML treatments. ABBV AMGN Listed as a key company in the AML market, suggesting active involvement in the development of AML therapies. GILD Identified as a key company in the AML market, implying ongoing research and development in the acute myeloid leukemia space. BMY AZN Listed as a key company in the CLL market, suggesting active research and development in chronic lymphocytic leukemia. INCY Identified as a key company in the CLL market, implying its participation in the development of CLL therapies. PFE Mentioned as a key company in the CML market, indicating its involvement in the development of chronic myeloid leukemia treatments. CELC Identified as a key company in the CML market, implying its participation in the development of CML therapies.

New York, USA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight

Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow, characterized by rapid growth of abnormal white blood cells. As AML primarily affects older adults, the global rise in aging populations is significantly increasing the at-risk patient base. This demographic shift is driving higher diagnosis rates and intensifying demand for more effective, better-tolerated treatments. Therefore, the market is seeing strong momentum in targeted therapies, immunotherapies, and personalized treatment approaches.

DelveInsight’s ' Acute Myeloid Leukemia Pipeline Insight 2025' report provides comprehensive global coverage of pipeline therapies for acute myeloid leukemia across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the acute myeloid leukemia domain.

Acute Myeloid Leukemia Clinical Trial Analysis Summary

Request a sample and find out what is the latest treatment for acute myeloid leukemia @ Acute Myeloid Leukemia Pipeline Report

What is Acute Myeloid Leukemia?

Acute myeloid leukemia (AML) is a cancer that impacts the bone marrow and blood. In this condition, the bone marrow produces abnormal myeloid cells, immature white blood cells that would normally mature into red blood cells, white blood cells, and platelets. These abnormal cells multiply quickly, crowding out healthy blood cells and disrupting normal bone marrow function. As a result, the body experiences a shortage of normal blood cells, leading to a range of symptoms and complications. Common signs and symptoms of AML include fatigue, weakness, shortness of breath, easy bruising or bleeding, frequent infections, fever, and unintentional weight loss. These symptoms arise from both the reduced number of healthy blood cells and the accumulation of abnormal cells in the marrow and bloodstream. AML can advance rapidly, making early diagnosis and treatment essential.

Find out more about acute myeloid leukemia drugs @ Acute Myeloid Leukemia Treatment

A snapshot of the Pipeline Acute Myeloid Leukemia Drugs mentioned in the report:

Learn more about the acute myeloid leukemia treatment success rate @ Acute Myeloid Leukemia Clinical Trials

Recent Developments in Acute Myeloid Leukemia Treatment Space

Scope of the Acute Myeloid Leukemia Pipeline Report

Dive deep into rich insights for new acute myeloid leukemia therapy, visit @ Acute Myeloid Leukemia Treatment Medicine

Table of Contents

For further information on the acute myeloid leukemia medications, reach out @ Acute Myeloid Leukemia Treatment Drugs

Related Reports

Acute Myeloid Leukemia Epidemiology Forecast

Acute Myeloid Leukemia Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted acute myeloid leukemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AML companies, including CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, Inc., Kartos Therapeutics, Inc., Celyad Oncology SA, Merck Sharp & Dohme LLC, Celgene, AbbVie, Genentech, Wugen, Inc., Arcellx, Inc, NextCure, Inc., Bellicum Pharmaceuticals, ImmunoGen, Inc., Astellas Pharma Inc, Aptose Biosciences Inc, Ascentage Pharma Group Inc., BioSight Ltd., GlycoMimetics Incorporated, Gilead Sciences, Chimerix, Daiichi Sankyo, Ryvu Therapeutics SA, Syros Pharmaceuticals, PrECOG, LLC, Cleave Therapeutics, Inc., Kronos Bio, Cullinan Oncology, LLC, Actinium Pharmaceuticals, Amgen, In8bio Inc, Sellas Life Sciences Group, Kura Oncology, Inc., Arog Pharmaceuticals, Inc., Novo Nordisk A/S, Marker Therapeutics, Inc., Shattuck Labs, Inc., Oncoceutics, Inc., among others.

Relapsed/Refractory Acute Myeloid Leukemia Market

Relapsed/Refractory Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key R/R AML companies, including Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, among others.

Chronic Lymphocytic Leukemia Market

Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic lymphocytic leukemia companies, including Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, among others.

Chronic Myeloid Leukemia Market

Chronic Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic myeloid leukemia companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals and Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn